NEW YORK (GenomeWeb) – ArcherDX and Ambry Genetics said today that they plan to partner to offer immune repertoire sequencing services to biopharmaceutical customers.
Under the agreement, Ambry will use ArcherDX's Immunoverse and VariantPlex next-generation sequencing assays for immune repertoire sequencing and chimeric antigen T cell receptor manufacturing characterization.
The assays are based on ArcherDX's anchored multiplex PCR technology and target B and T cell receptor complementarity-determining regions in order to quantify changes in the immune repertoire and target CAR-T vectors. The assays can be used to target CAR-T vectors to understand the T cell repertoire throughout the course of treatment and manufacturing of autologous CAR-T cells.
"The ability to characterize CAR-T cells at this resolution provides an unprecedented level of quality control to the T cell engineering process," Phillip Gray, vice president of advanced genomic services at Ambry, said in a statement.